Pluristem Therapeutics to Present at "The Stem Cell Network" Conference
NEW YORK, Mar 17, 2009 (BUSINESS WIRE) -- Pluristem Therapeutics Inc. (NasdaqCM: PSTI) (DAX: PJT), a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for a variety of disorders, announced today that William Prather RPh, MD, Pluristem's Senior Vice President for Corporate Development, has been invited to be a featured speaker at "The Stem Cell Network" conference. The title of the conference is "Stem Cell Therapy - The Future of Medicine" and it will be held on March 19, 2009 at the Marriot Del Mar Hotel in San Diego, California. Dr. Prather will present an overview of Pluristem and an update on the clinical development of the Company's placental-derived (PLX) stem cells. Other featured speakers at the event include Robert Klein JD, Chairman of the Governing Board of the California Institute of Regenerative Medicine and Robert Harman DVM, CEO of Vet Stem, Inc.
About "The Stem Cell Network"
The Stem Cell Network is an industry forum established for the support and advancement of the stem cell industry. The focus of the organization is to introduce the stem cell community to business and community leaders to further the growth and development of stem cell research. The Stem Cell Network believes that research in this area has the potential to revolutionize the medical industry and its mission is to provide a pathway to expose this potential to the world.
About Pluristem
Pluristem Therapeutics Inc. is a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from human placenta, a non-controversial, non-embryonic, adult stem cell source.
These placental adherent stromal cells (ASCs) are expanded in the Company's proprietary PluriX(TM) 3D bioreactor, which imitates the natural 3D microenvironment of these cells and does not require supplemental growth factors or other exogenous materials. Pluristem believes that the resultant PLX (PLacental eXpanded) cells' efficacy may be related to the secretion of cytokines or other potent immune modulators. Furthermore, PLX cells are immune privileged and possess immunomodulatory properties, thus protecting the recipient from immunological reactions that often accompany transplantations.
Pluristem's first product in development, PLX-PAD, is intended to improve the quality of life of millions of people suffering from peripheral artery disease (PAD). The Company's products in development also include PLX-IBD, targeting Inflammatory Bowel Disease (IBD); PLX-MS, targeting Multiple Sclerosis; PLX-BMT, targeting the global shortfall of matched tissue for bone marrow transplantation (BMT) by improving the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood; and PLX-STROKE, targeting ischemic stroke.
Pluristem has offices in the USA with research and manufacturing facilities in Israel.
See our product animation on YouTube: Animation |
